ArticleCardiovascular toxicology2025
Association of VEGFA Gene Polymorphisms with the Susceptibility of Coronary Heart Disease in the Chinese Han Population.
Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Coronary heart disease (CHD) is a prevalent cardiovascular' condition characterized by high morbidity and mortality rates, with a significant genetic component. The VEGFA gene plays a crucial role in the development of CHD. This study aims to evaluate the influence of VEGFA gene polymorphisms on CHD susceptibility. Peripheral blood samples were collected from 479 CHD patients and 479 healthy controls. We genotyped four VEGFA single nucleotide polymorphisms (SNPs): rs833068, rs833070, rs3025021, and rs3025030, using the Agena MassARRAY platform. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between these SNPs and CHD risk. Multifactor dimensionality reduction (MDR) was employed to analyze potential SNP-SNP interactions. The rs833068 SNP was found to be associated with a reduced risk of CHD (OR 0.46, p = 0.013), whereas the rs3025021 (OR 1.32, p = 0.031) and rs3025030 (OR 1.30, p = 0.032) SNPs were linked to an increased risk. The stratified analysis revealed that rs833068 decreased CHD risk in individuals aged < 61 years, those with a BMI ≥ 24, non-smokers, non-drinkers, and patients with diabetes, but increased the risk in hypertensive individuals. The rs833070 SNP significantly increased CHD risk in non-smokers and non-drinkers. Rs3025021 was associated with an increased CHD risk in subjects with a BMI < 24, smokers, drinkers, and diabetics. Rs3025030 was found to increase CHD susceptibility in aged > 61 years, males, those with a BMI ≥ 24, and drinkers. MDR analysis identified a combination of rs833068, rs3025021, and rs3025030 as the most predictive model for CHD. Polymorphisms in the VEGFA gene are associated with CHD risk in the Chinese Han population, offering a novel perspective for CHD diagnosis.
Indexed as
Identifiers
40445573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.